Many patients with severe angina experience inadequate response to pharmacological approaches and require surgical treatment such as PCI with or without stenting, or CABG. Many patients with chronic, severe angina are not candidates for PCI or CABG because of a variety of reasons including failed prior procedures, diffuse coronary artery disease, distal stenosis or extremely small coronary arteries. These patients represent the primary target population for treatment with TMR.
Transmyocardial revascularization (TMR) is a surgically performed laser-based heart treatment procedure in which transmural channels are made in the heart muscle. Many scientific experts believe that these procedures encourage new vessel formation, also known as angiogenesis. TMR therapy is approved for patients suffering from chronic or severe angina. The American Heart Association (AHA) estimates that approximately 9.8 million Americans experience angina symptoms.